|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1987-4-6
|
|
pubmed:abstractText |
The E3 19,000-dalton protein termed "E3/19K" of adenovirus type 2 binds to human class I histocompatibility antigens (HLA antigens). Human 293.12 cultured cells that express a cloned gene for the E3/19K protein show reduced levels of HLA antigens on the cell surface compared to parental 293 cells. We have transfected these cell lines with plasmid DNA containing the murine histocompatibility H-2Kd allele to demonstrate that this antigen binds also to the E3/19K protein. The resulting association prevents the H-2Kd antigen from being terminally glycosylated and inhibits its cell-surface expression. Two murine cytolytic T-lymphocyte clones specific for HLA antigens and restricted by the H-2Kd antigen lyse the human 293Kd cells. In the presence of the E3/19K protein, a dramatically reduced cell surface density of both HLA and H-2Kd antigens was shown. This decreased amount of cell-surface HLA/H-2Kd antigens correlated with a reduction in susceptibility to lysis of the target cells. In particular, the cell-surface level of the H-2Kd antigen, which is the restricting element, was crucial for efficient lysis. Thus, the E3/19K protein of adenovirus type 2 indirectly reduces the cellular immune recognition in the in vitro system. This might be the mechanism involved in latent and persistent infections caused by adenoviruses in vivo.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-104386,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-11894934,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-13533400,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-2934137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-2982951,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-2987009,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-3079884,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-3086429,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-310123,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-367435,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-3924414,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-3929396,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6088078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6183366,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6286831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6287288,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6305511,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6314265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6336330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6478856,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-667938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6885796,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6935293,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6955026,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-6985478,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-7000762,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-7016338,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-7135466,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-7365790,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-886304,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2950523-92183
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
84
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1356-60
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2950523-Adenovirus E3 Proteins,
pubmed-meshheading:2950523-Adenoviruses, Human,
pubmed-meshheading:2950523-Animals,
pubmed-meshheading:2950523-Cell Transformation, Neoplastic,
pubmed-meshheading:2950523-Clone Cells,
pubmed-meshheading:2950523-Cytotoxicity, Immunologic,
pubmed-meshheading:2950523-HLA Antigens,
pubmed-meshheading:2950523-Humans,
pubmed-meshheading:2950523-Kidney,
pubmed-meshheading:2950523-Major Histocompatibility Complex,
pubmed-meshheading:2950523-Mice,
pubmed-meshheading:2950523-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:2950523-Transfection,
pubmed-meshheading:2950523-Viral Proteins
|
|
pubmed:year |
1987
|
|
pubmed:articleTitle |
"E3/19K" protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
